Compare Becton Dickinson and Co (BDX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Procter & Gamble Co — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Procter & Gamble Co trades at $146.14 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 7× Becton Dickinson and Co's market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| BDX | PG | |
|---|---|---|
Market Cap | $48.93B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $167.18 |
52-Week Low | $138.62 | $138.10 |
Enterprise Value | $65.03B | $366.23B |
Dividend Yield | 2.34% | 2.97% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Procter & Gamble (PG) trades at $145.21, down 0.38% on the day, with a bearish technical signal from moving averages. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.43 beating expectations of $1.41. Revenue reached $84.28 billion in 2025 with net income of $15.97 billion, supported by a robust 18.44% net margin and 30.13% ROE. Recent developments include a new WNBA partnership and a $1.09 dividend declaration for August 2026 payment.
PG offers stable dividend income with 69 consecutive years of increases, but faces premium valuation concerns at 22.12 P/E ratio. Analyst consensus targets $161.20 with 53% buy ratings, suggesting 11% upside potential. Key risks include soft demand outlook and elevated valuation multiples compared to peers. The stock presents a defensive investment opportunity amid market volatility, though near-term growth appears modest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
